The Catalent Institute and drug delivery experts from Catalent Pharma Solutions, 3M, Saarland University and Lipp Life Sciences presented topics surrounding bioavailability enhancement, advanced drug delivery methods and patient centric drug design.
Participants had the opportunity to bring their toughest drug development challenges to discuss with the expert panel, have a tour of the 3M Innovation Center and network with other scientists from industry and academia.
8:30 AM – 9:00 AM | Registration and Breakfast
9:00 AM – 9:15 AM | Welcome & Introduction
9:15 AM – 10:45 AM | Drug Delivery Methods: Transdermal Applications & Vaccine Delivery
- Microneedles for intradermal drug delivery
- Transfollicular delivery of vaccines
10:45 AM – 11:00 AM | Break
11:00 AM – 11:45 AM | “The use of novel toll-like receptor agonists & microneedle delivery systems to increase effectiveness of vaccines”
11:45 AM – 12:30 PM | Guided Tour (round 1) – Networking Lunch & Meet the Experts
12:30 PM – 1:15 PM | Guided Tour – (round 2) – Networking Lunch & Meet the Experts
1:15 PM – 2:45 PM | Bioavailability Enhancement Tools
- “Lipid-based drug delivery for poorly water soluble compounds”
- “Improving solubility at high doses using hybrid nanoparticles”
2:45 PM – 3:00 PM | Break
3:00 PM – 3:45 PM | “Micronized particle applications to overcome bioavailability challenges” & case studies
3:45 PM – 4:30 PM | Patient-Centric Drug Design
- “How to use insights from patient needs to design drugs/medical systems which deliver better outcomes”
4:30 PM – 5:00 PM | Expert Panel Discussion
- “Evolving drug delivery landscape”
- Closing remarks
Executive Director, Catalent Institute
Ms. Robinson has over 25 years of experience in pharmaceutical strategy, development and program management. Her expertise includes bringing business and technical leaders together to create shared vision and achieve mutual objectives. Prior to her current role, Ms. Robinson was Executive Director of Global Accounts responsible for Catalent’s largest strategic customers and was named Executive Director of the Catalent Applied Drug Delivery Institute as of February 2013. Ms. Robinson holds a Bachelor’s degree in Psychobiology as well as a Certificate in Aging Studies from The University of Virginia.
Executive Board Member, Catalent Institute R&D Platform Director, Rx Softgel
Julien Meissonnier has 15 years of experience in pharmaceutical development and leads Catalent’s European R&D Platform for the development of lipid-based drug delivery solutions. He provides technical and scientific leadership for the development of poorly soluble drugs that lead to approvable regulatory dossiers. Mr. Meissonnier received his Engineering Degree in Physico-Chemistry from the ISMRa in Caen, France. He is an expert in his field and currently sits on the Board of Directors with the Alsace BioValley life sciences and healthcare cluster based in France. As a board member, he supports Alsace BioValley in its efforts to continue driving growth in the life sciences by identifying and coordinating ambitious projects that will create employment opportunities in the region.
Dr. Mark Tomai
3M, Transdermal Delivery
Mark Tomai has a PhD in immunology from the University of Minnesota. For the past eight years he has been Head of Microneedle and Toll-like Receptor Business Development at 3M Drug Delivery Systems. During his first 16 years in the industry he held a variety of positions with increasing responsibility in drug discovery and preclinical development. He is an author on over 80 publications and is an inventor on 12 issued patents in this area.
Dr. Claus-Michael Lehr
Professor & Head, Dept. of Drug Delivery (DDEL), Saarland University
Dr. Claus-Michael Lehr, professor and head of the department of drug delivery (DDEL), Saarland University and advisory board member of Catalent Institute has spent more than 15 years leading research into ways to overcome biological barriers to effective drug delivery, and the development and formulation of appropriate carriers to transport active pharmaceutical and biopharmaceutical molecules to desired targets. He has co-authored many notable publications on the development of sophisticated in-vitro models that more accurately represent the epithelial cells and tissues concerned in transport, and the application of nanotechnology to improve in-vivo delivery to such therapeutic targets.
Dr. Kirsty Gapp
TDD Platform Leader, 3M
Dr. Gapp’s background is in molecular biology and microbiology. She has held various technical and commercial roles within 3M Health Care focusing mainly on medical devices. Dr. Gapp’s current role is overseeing 3M’s Transdermal Drug Delivery platform in EMEA, including microneedle technology.
Dr. Ralph Lipp
Founding Advisory Board Member, Catalent Institute, President & CEO of Lipp Life Sciences, LLC
Dr. Ralph Lipp has more than 20 years of experience in the life sciences industries. Before founding Lipp Life Sciences LLC, where he advises clients on innovation-based value creation, he served as Vice President Pharmaceutical Sciences R&D at Eli Lilly and Company and Head Pharmaceutical Development at Schering AG. He holds a degree in Pharmacy from Johannes Gutenberg University (Germany) and obtained a Ph.D. in Medicinal Chemistry as well as a Habilitation for Pharmaceutical Technology from Free University Berlin (Germany). He graduated from INSEAD’s (France) International Executive Program and from Harvard Business School’s (USA) Advanced Management Program. Ralph’s scientific contributions comprise over 120 publications, including more than 20 patents, covering 5 marketed medicines.
Dr. Elanor Pinto
Ph.D., Technical Project Manager, Catalent Micron Technologies
Elanor Pinto, Ph.D. is the technial lead in Quality-by-Design services to optimize and validate commercial manufacturing for clients using Catalent Micron Technologies particle reduction cGMP services. In addition, she provides preformulation and post-formulation trouble-shooting and consulting surrounding API particle reduction technologies. In prior work, Elanor was a Senior Staff Scientist at Ashland and provided technical service and consulting in pharmaceutical formulation development with cellulosics and poly-vinyl polymers and its derivatives. She obtained her PhD from University of Florida’s Pharmaceutics department with her thesis on “Sustained Release of a small lipophilic drug using poly(lactic-co-glycolic) acid (PLGA) polymer microspheres as a drug delivery system for localized delivery.” Elanor has authored/co-authored more than 5 scientific papers and book chapters in the field of formulation development and pharmaceutical technology. She has presented several posters and podium presentations at national workshops and meetings. Elanor is the current Chair for the AAPS (American Association of Pharmaceutical Scientists) Modified Release Focus Group. She was the 2012 and 2013 Chair of the Eastern Pharmaceutical Technology Meeting (Basking Ridge, NJ).